- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01262781
Is Fructose Linked to Adiposity in Babies? (FLAB)
Study Overview
Status
Conditions
Detailed Description
The "fetal origins hypothesis" suggests that an individual's risk for obesity and metabolic disorders begins in utero; that fetal or early postnatal exposure to environmental factors, such as maternal nutrition or endocrine disrupting chemicals, adversely influences early development and results in permanent changes affecting energy storage and expenditure.
Most studies on "fetal origins" of obesity in the offspring have focused on maternal high-fat diets; yet dietary fat consumption has not changed appreciably in the last two decades. One chemical exposure in both pregnant mothers and newborns that has been steadily increasing worldwide is fructose. Although ostensibly a carbohydrate, fructose is a potent lipogenic substrate, and in the hypercaloric state, as much as 30% of an ingested fructose load undergoes de novo lipogenesis to form triglyceride thus the effects of high-fat and high-fructose diets in terms of physiology and outcome are comparable. Substituting sucrose (fructose + glucose) for glucose alone increases visceral adiposity, insulin resistance, and dyslipidemia in adult animals and humans. For humans, fructose is ubiquitous in the food environment, especially for pregnant mothers, who are often counseled to drink juice during pregnancy, as it is deemed to be healthier than soda. The effects of fructose consumption during pregnancy on infant birth weight and adiposity has not yet been studied.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- San Francisco General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Agreement to participate in all measurements
- Plans to remain in the area through delivery
- Ability to understand and give informed consent in either English or Spanish.
Exclusion Criteria:
- Presence of diabetes prior to the index pregnancy
- Presence of gestational diabetes during a previous pregnancy
- Presence of diabetes or of other chronic metabolic disease such as cardiovascular disease, active thyroid disease, liver disease, pulmonary or psychiatric disorders, HIV
- Any disorder requiring diet therapy (i.e., renal insufficiency)
- Multiple gestation
- Prior history of intrauterine growth retardation
- Use of substances known to cause intrauterine growth retardation (e.g., smoking or drug use). -
- Once recruited, any ultrasonographic evidence of intrauterine growth retardation during the course of the pregnancy would also lead to exclusion.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
% adiposity (DEXA)
Time Frame: After delivery, neonatal adiposity will be measured using DEXA. This part of the protocol takes place 4-5 months after recruitment.
|
After delivery, neonatal adiposity will be measured using DEXA.
|
After delivery, neonatal adiposity will be measured using DEXA. This part of the protocol takes place 4-5 months after recruitment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cord blood insulin (corrected by cord blood glucose)
Time Frame: At delivery (in the OR): 4-5 months after recruitment
|
At delivery (in the OR): 4-5 months after recruitment
|
|
|
cord blood triglycerides
Time Frame: At delivery (in the OR): 4-5 months after recruitment
|
At delivery (in the OR): 4-5 months after recruitment
|
|
|
cord blood leptin
Time Frame: At delivery (in the OR): 4-5 months after recruitment
|
At delivery (in the OR): 4-5 months after recruitment
|
|
|
anthropometric measurements on the newborn
Time Frame: After delivery (4-5 months after recruitement)
|
birth weight, arm, thigh, and abdominal circumference, subscapular skinfolds
|
After delivery (4-5 months after recruitement)
|
|
fetal fractional thigh volume obtained by fetal ultrasound
Time Frame: At 32 weeks gestation (4 months after recruitment)
|
The fetal fractional thigh volume will me measured in addition to routine fetal measurements at 32 weeks estimated gestation age.
This measurement is a measure of neonatal adiposity.
|
At 32 weeks gestation (4 months after recruitment)
|
|
cord blood uric acid
Time Frame: At delivery (in the OR): 4-5 months after recruitment
|
At delivery (in the OR): 4-5 months after recruitment
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Anjali Jain, MD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SFGH 6281
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.